Bezoloven

Bezoloven, Inc. was a virtual biotechnology company founded in 2007 to develop a reformulated, grape-flavored version of d-penicillamine for the treatment of low-level lead poisoning in children. Established by angel investor Roger Kitterman in collaboration with Dr. Michael Shannon of Children's Hospital Boston, the company aimed to address a significant gap in pediatric toxicology by providing a more palatable and effective chelation therapy. The company operated as a shell entity to fund specific clinical trials in partnership with Tedor Pharma, a contract development and manufacturing organization. Its lead program reached Phase 2 clinical testing before the trial was ultimately withdrawn. Following the withdrawal of its clinical program and the passing of its scientific lead, the company is no longer active in drug development.